Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

Inclusion Criteria

• •Histologic or cytologic diagnosis of extensive stage SCLC.
• •Measurable or assessable tumor parameters.
• •ECOG Performance Status 0-2.
• •Age between 18 and 79 years (in the State of Alabama \> 18).
• •Adequate bone marrow, liver and renal function, defined as:
• •Absolute neutrophil count (ANC) ≥ 1500/µL
• •Hemoglobin ≥ 8g/dl
• •Platelet count ≥ 100,000/µL
• •SGOT/SGPT ≤ 2 x upper limit of normal or ≤ 5 x upper limit of normal when liver metastases are present.
• •Total bilirubin value ≤ 2 x upper limit of normal.
• •Serum creatinine value ≤ 2 x upper limit of normal.
• •Fully recovered from any previous surgery (at least 4 weeks since major surgery)
• •Must have recovered from prior radiation therapy (at least 3 weeks)
• •All subjects must agree to practice approved methods of birth control (if applicable). A negative pregnancy test must be documented during the screening period for women of childbearing potential.
• •Must provide written informed consent and authorization to use and disclose health information (HIPAA).
• •Extensive-stage SCLC as defined as disease not confined to one hemithorax, including ipsilateral pleural effusion or pericardial effusion.
• •No prior chemotherapy.